1. Hansson L, Hedner T, Dahlof B (1992) Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end-point. Blood Press 1(2):113–119
2. Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J (2003) Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 21(7):1291–1298.
https://doi.org/10.1097/01.hjh.0000059068.43904.0a
3. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB, International Committee of Medical Journal Editors (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Croat Med J 45(5):531–532
4. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P (2009) Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 302(9):977–984.
https://doi.org/10.1001/jama.2009.1242
5. De Oliveira GS Jr, Jung MJ, McCarthy RJ (2015) Discrepancies between randomized controlled trial registry entries and content of corresponding manuscripts reported in anesthesiology journals. Anesth Analg 121(4):1030–1033.
https://doi.org/10.1213/ANE.0000000000000824